# A Study to Assess the Effect of Hepatic Impairment on Safinamide Pharmacokinetics

> **NCT01027169** · PHASE1 · COMPLETED · sponsor: **Newron Pharmaceuticals SPA** · enrollment: 24 (actual)

## Conditions studied

- Hepatic Impairment

## Interventions

- **DRUG:** safinamide
- **DRUG:** safinamide
- **DRUG:** safinamide

## Key facts

- **NCT ID:** NCT01027169
- **Lead sponsor:** Newron Pharmaceuticals SPA
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-04
- **Primary completion:** 2009-10
- **Final completion:** —
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2013-03-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01027169

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01027169, "A Study to Assess the Effect of Hepatic Impairment on Safinamide Pharmacokinetics". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01027169. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*